Professors Klaus Schmierer and Helen Ford want to answer your ChariotMS questions
Traditionally, clinical trials for MS haven't included people who depend on a wheelchair to get around. But this is changing. Now you can find out more about the first clinical trial specifically for people with advanced MS at a special webinar!
ChariotMS is a phase 2 trial testing whether cladribine can help people with more advanced MS maintain the use of their arms and hands. Cladribine (brand name Mavenclad) is already licensed for highly active relapsing MS.
Consultant Neurologist and MS researcher, Professor Klaus Schmierer, is leading the trial. He's recruiting 200 people who have an EDSS (Expanded Disability Status Scale) score of 6.5 to 8.5 to take part. It’s the first trial of its kind with no upper age limit. And people will be able to take part at lots of hospitals around the UK.
A chance to ask your burning questions
On Tuesday 19th April 2022, Klaus and his team are hosting a special webinar for people to find out more about ChariotMS.
They'll be joined by Professor Helen Ford, who leads the ChariotMS hospital site in Leeds. Helen is a Consultant Neurologist and also works on other trials for progressive MS, including MS-STAT2.
Klaus and Helen will talk about the research behind ChariotMS and what’s involved in taking part in a trial like this – as well as answering any burning questions!
How to sign up for the webinar
To sign up, you just need to complete a short form on Eventbrite by clicking the button below.
The team will be using Zoom to hold the webinar. All you need to join in is a laptop, tablet, phone or computer with an internet connection. Before the event, they'll send you an email with a link to the Zoom meeting. At the time the webinar is due to start, click on the link and you'll be taken to the webinar.
What if I can't attend?
If you can't attend the webinar and you think you might be eligible to join the trial, you can email the team at [email protected].
